WHO ICTRP trial
TWO VERSUS ONE DRUG FOR CONTROL OF SWELLING IN NEPHROTIC SYNDROME.
CTRI/2023/05/052552 · Clinical Trials Registry India (CTRI) · Recruiting
Key facts
| Trial ID | CTRI/2023/05/052552 |
|---|---|
| Public title | TWO VERSUS ONE DRUG FOR CONTROL OF SWELLING IN NEPHROTIC SYNDROME. |
| Scientific title | COMBINATION THERAPY WITH FUROSEMIDE AND METOLAZONE AS COMPARED TO FUROSEMIDE ALONE FOR TREATMENT OF EDEMA IN CHILDREN WITH NEPHROTIC SYNDROME: A RANDOMISED CONTROL TRIAL |
| Primary sponsor | AIIMS Bhubaneswar |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Countries | India |
| Conditions | Health Condition 1: N040- Nephrotic syndrome with minor glomerular abnormality |
| Interventions | Intervention1: Group A: Children randomly allocated to group A will receive Metolazone @ 0.3 mg/kg/day orally in 1-2 divided doses along with Furosemide @ 2 mg/kg/day IV in two divided doses Control Intervention1: Group B: Children randomly… |
| Registration date | Dec 5, 2023 |
| Target size | 50 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: